Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Related Content
New Strategies for a Better Glycosylation Profile
January 22nd 2025Article
Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.
